EBF 2021 -- Multi-domain biologics can potentially induce anti-drug antibodies (ADA) with specificity to different domains. Domain-specific ADA may differently affect drug efficacy and safety, and thus characterization of ADA domain specificity has become a regulatory expectation during clinical development of multi-domain biologics.